Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... announced that AlloWrap® DS, its double-sided human amniotic ... reimbursement category. "Reimbursement helps ensure ... said Kimberly French , Director of Marketing ...
(Date:5/28/2015)... 28, 2015 Research ... addition of the  "North America Ultrasound Devices ... - 2019)"  report to their offering.  ... is a type of imaging. It uses ... parts and structures inside the body. Health ...
(Date:5/28/2015)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... the Jefferies 2015 Healthcare Conference on Wednesday, June 3, ... New York .  Lexicon management will provide an ... A webcast of the presentation will be available ... version of the presentation will be available at ...
Breaking Medicine Technology:AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2North America Ultrasound Devices Market Report 2014-2019 - Technology and Applications 2Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... Suffering from these Diseases, LOS ANGELES, March ... are two serious and debilitating,diseases with no confirmed ... new comprehensive literature study propose a simplified,treatment process ... these diseases., Kent Holtorf, M.D., medical director ...
... Data Presented at SIR Meeting Indicates New Catheter-based, ... Care for Treating Acute DVT, WASHINGTON, March ... the Society of Interventional Radiology,s 33rd Annual,Scientific Meeting ... from Bacchus Vascular, Inc. (Santa Clara, CA) successfully,breaks ...
Cached Medicine Technology:Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia 2Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia 3Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients 2
(Date:5/28/2015)... (PRWEB) May 28, 2015 Three years ago, ... location for his Shore Vascular & Vein Center! ... circulatory system. It is his mission to provide the ... respect. , Dr. Jeffrey Gosin is Board Certified ... the University of Pennsylvania and Jefferson Medical College. He completed ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 AMVETS leaders ... grand prize winner Robert Davis of Newark, Del. AMVETS ... congratulate him on winning the $10,000 sweepstakes grand prize. ... over 100,000 entries from around the country for prizes ... drawing took place on May 21 at the AMVETS ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... ISMETT , a leading transplant hospital managed ... economy by €132.5 million in expenditure in 2013, generated nearly ... €73 million by retaining patients who otherwise would have traveled ... by the Battelle Memorial Institute. At the same time, the ... health care management that is transforming Sicily into a biomedical ...
(Date:5/28/2015)... May 28, 2015 " Trends Investing ” ... Report, which takes a look at small, medium, and large ... host of NewsWatch and business expert, conducted the business review ... users to where they should invest their money. , The ... concept. But doing it and knowing how to succeed ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2
... A new fitness campaign for older Americans has been introduced by ... meant to encourage people 50 and older to become and stay ... for maintaining health and independence as people age, but regular physical ... to 64; 25 percent of those aged 65 to 74; and ...
... dementia have in common? Perhaps more than meets the eye, ... A diverse group of scientists experts in ... to study drugs that show promise in the treatment of ... heart failure. In this case, the connection between the head ...
... Wayne State University,s Parent Health Lab in the School ... identifies women at risk for drug use by evaluating ... itself. In phase I testing, this new screener proved ... detecting recent drug use. The team of researchers also ...
... in Spanish . Functional psychosis ... patient, thanks to affective symptomatology. Depressive moods, hyperactivity and ... themselves during the first psychotic episodes, and the presence ... differentiating, at an early stage, between the different variations ...
... COLUMBUS, Ohio Researchers at Ohio State University Medical Center ... to deliver a gene into the eyes of people born ... males. , The vector is part of a clinical ... a disease that affects an estimated 100,000 people worldwide. The ...
... Arbor, Mich. -- A University of Michigan Health System laboratory ... cells that could lead to a new treatment for those ... mice, appears in this week,s early edition of the ... promise for preventing the painful episodes and organ damage that ...
Cached Medicine News:Health News:Older Americans Encouraged to Get Fit 2Health News:Scientists explore whether what heals the head can also heal the heart 2Health News:Scientists explore whether what heals the head can also heal the heart 3Health News:Wayne State creating computer-based drug intervention for at-risk post-partum women 2Health News:Precise early diagnosis of psychotic disorders possible 2Health News:Ohio State researchers design a viral vector to treat a genetic form of blindness 2Health News:Researchers reveal potential treatment for sickle cell disease 2
Cushing forceps. Insulated....
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size....
Fechtner Trabeculectomy Marker...
... when rotated at 8-10 rpm. Drums ... Light weight drum of professional quality ... mechanism. For use 24 to 30 ... and Pediatric Drums that can be ...
Medicine Products: